Step 1: Check Patient Eligibility 

Eligibility for these tests is determined according to the National NHS England » National genomic test directory - see rare and inherited disease eligibility criteria. If, after accessing the directory and the toolkit, you are unclear about eligibility or sample arrangements, please contact SWGLHcancer@nbt.nhs.uk and we will be glad to support you. 

(Note: these toolkits are for germline tests. For somatic tests see SWGLH Requesting a Genomic Test for Solid Tumours)

Step 2: Consent the patient

Germline genetic tests have implications for future and family health. Patients should be informed of the implications and appropriately consented, using a tool such as the Mainstreaming Consent Form to document in the patient record. The below Patient information leaflet can be used with or without local trust logo to support patient information provision. 

Patient Information Leaflet – R207 Patient Information Leaflet V1 GLH LOGO: 

Patient Information leaflet with the option to add your Trust Logo: 

Printing Guidance for Patient Information Sheets

• Print in landscape.
• Print on both sides.
• Flip on short edge.

Step 3: Arranging samples and completing the test request form

Blood samples in EDTA tubes (2 x 4ml for adults, 2-5ml for children and 1-2ml for neonates) are required for these tests. Samples should be kept at room temperature or at 4oC and not be frozen before dispatch. 

Please ensure all sample tubes are labelled and accompanied by the test request form

Complete the SWGLH Genomic Test Request form, including:

• The test required.
• Patient diagnosis (confirming eligibility).
• Any relevant family history.
• Who the result should be returned to - a shared results email account for your team is recommended .

Send the completed form with samples:

Step 4: Transportation of samples to the SWGLH

Samples should be transported to the SWGLH through your local pathology systems, unless advised otherwise. These samples should be kept at room temperature or at 4oC and should not be frozen before dispatch. They should ideally arrive within 3 days of sample collection.  

Please refer to the SWGLH Sample Requirements and Transport page for further information. 

Step 5: Results and turnaround times

Results will be returned to the email account or clinician listed on the form

• The national turnaround time for these tests is 42 working days, from sample receipt. Current turnaround times for some tests are considerably shorter than this.
• When special circumstances require a more urgent result, please flag this on the form and contact the Bristol Genetics laboratory to discuss the best approach.
• Once resultsmailto:ubh-tr.clinicalgeneticsuhb@nhs.net are received, please see your local mainstreaming guidance for information on management and Clinical Genetics involvement. If you need advice, contact your local Clinical Genetics service: 

Devon and Cornwall region: rduh.pcgreferrals@nhs.net (or via the Epic system if you are based at the Royal Devon University Healthcare NHS  Foundation Trust)

Bristol region: UHBWClinicalGenetics@uhbw.nhs.uk

Step 1: Check Patient Eligibility

Eligible tumours and the available tests are shown in the National Genomic Test Directory for Cancer (NGTD).

Step 2: Consent the patient

Germline genetic tests have implications for future and family health. Patients should be informed of the implications and be appropriately consented, using a tool such as the Mainstreaming Consent Form to document in the patient record. The below patient information leaflet can be used with or without local trust logo to support patient information giving. 

Mainstreaming R208 Consent Form: 

Patient Information Leaflet – Genomic testing Inherited cancer R208 with SWGLH logo: 

Patient Information Leaflet - Genomic testing Inherited cancer R208 with space for Trust logo:

• R208 Patient Information Leaflet V1.2 Trust Logo.pdf190.85 KB

Printing Guidance for Patient Information Sheets

• Print in landscape
• Print on both sides
• Flip on short edge

BReast CAncer Genes and Me  

‘BReast CAncer Genes and Me’ is a digital patient empowerment project that’s set to transform the experience of people with a diagnosis of breast cancer that might have implications on other family members.

The project introduces the concept of genetic testing for breast cancer in an accessible format, presented as a six-part series of colourful animations. Each video features digestible information accompanied by gentle music and a clear voiceover that takes the participant through the process and implications of genetic testing.

This project has been developed as part of a Collaborative Working initiative between the South West Genomic Medicine Service Alliance and AstraZeneca UK, and has been co-designed by clinicians and patients alike, providing an overview of the genetic testing pathway from start to finish. We have been working with Magentus Global Health Tech for our digital solution. 

BReast CAncer Genes and Me aims to streamline the consent process for breast cancer genetic testing through a digital consent pathway, supporting patients and their families through every stage and guiding them to become confident decision-makers.

View the videos on our YouTube channel.
 

Step 3: Arranging samples and completing the test request form

Blood samples in EDTA tubes (2 x 4ml for adults, 2-5ml for children and 1-2ml for neonates) are required for these tests. Samples should be kept at room temperature or at 4oC and not be frozen before dispatch. 

Please ensure all sample tubes are labelled and accompanied by the test request form

Complete the SWGLH Genomic Test Request form, including:

• The test required.
• Patient diagnosis (confirming eligibility).
• Any relevant family history.
• Who the result should be returned to - a shared results email account for your team is recommended .

Send the completed form with samples:

• GMS Test Order Form v2.3.pdf1.77 MB

Step 4: Transportation of samples and request form to the SWGLH

Samples should be transported to the SWGLH through your local pathology systems, unless advised otherwise. These samples should be kept at room temperature or at 4oC and should not be frozen before dispatch. They should ideally arrive within 3 days of sample collection.  

Please refer to the SWGLH Sample Requirements and Transport page for further information. 

Step 5: Results and turnaround times

Results will be returned to the email account or clinician listed on the form

The national turnaround time for these tests is 42 working days, from sample receipt. Current turnaround times for some tests are considerably shorter than this.

When special circumstances require a more urgent result, please flag this on the form and contact the Bristol Genetics laboratory to discuss the best approach.

Once results are received, please see your local mainstreaming guidance for information on management and Clinical Genetics involvement. If you need advice, contact your local Clinical Genetics service:

rduh.pcgreferrals@nhs.net (or via the Epic system if you are based at the Royal Devon University Healthcare NHS Foundation Trust)

UHBWClinicalGenetics@uhbw.nhs.uk

Educational resources

Competency frameworks for cancer genomics are available on the Genomics Education programme website.

Step 1: Check Patient Eligibility 

Eligible tumours and the available tests are shown in the National Genomic Test Directory for Cancer (NGTD).

Step 2: Consent the patient

Germline genetic tests have implications for future and family health. Patients should be informed of the implications and be appropriately consented, using a tool such as the Mainstreaming Consent Form to document in the patient record. The below patient information leaflet can be used with or without local trust logo to support patient information giving. 

Please use the mainstreaming R208 Consent Form: 

• Patient Information Leaflet – Patient Information Leaflet – R444 (Breast Cancer) PIS with SWGLH logo: 

• Patient Information Leaflet - Patient Information Leaflet – R444 (Breast Cancer) PIS with space for Trust logo: 

Printing Tips for Patient Information Sheets

• Print in landscape.
• Print on both sides.
• Flip on short edge.

Step 3: Arranging samples and completing the test request form

Blood samples in EDTA tubes (2 x 4ml for adults, 2-5ml for children and 1-2ml for neonates) are required for these tests. Samples should be kept at room temperature or at 4oC and not be frozen before dispatch. 

Please ensure all sample tubes are labelled and accompanied by the test request form

Complete the SWGLH Genomic Test Request form, including:

• The test required.
• Patient diagnosis (confirming eligibility).
• Any relevant family history.
• Who the result should be returned to - a shared results email account for your team is recommended.

Send the completed form with samples:

Step 4: Transportation of samples and request form to the SWGLH

Samples should be transported to the SWGLH through your local pathology systems, unless advised otherwise. These samples should be kept at room temperature or at 4oC and should not be frozen before dispatch. They should ideally arrive within 3 days of sample collection.  

Please refer to the SWGLH Sample Requirements and Transport page for further information. 

Step 5: Results and turnaround times

Results will be returned to the email account or clinician listed on the form

• The national turnaround time for these tests is 42 working days, from sample receipt. Current turnaround times for some tests are considerably shorter than this.
• When special circumstances require a more urgent result, please flag this on the form and contact the Bristol Genetics laboratory to discuss the best approach.
• Once results are received, please see your local mainstreaming guidance for information on management and Clinical Genetics involvement. If you need advice, contact your local Clinical Genetics service: 

rduh.pcgreferrals@nhs.net (or via the Epic system if you are based at the Royal Devon University Healthcare NHS Foundation Trust)

UHBWClinicalGenetics@uhbw.nhs.uk

Educational resources

Competency frameworks for cancer genomics are available on the Genomics Education programme website.

There are three different test codes depending on the reason for testing prostate patients. Please see the NGTD for eligibility criteria and select the appropriate test.
•    R430 - direct germline testing for patients who are eligible for panel testing based on personal or family history.
•    R444 - for patients being assessed for PARP inhibitor eligibility, where somatic testing has failed. 
•    R240 - for patients whose somatic test showed a gene variant. This test confirms whether the variant is present in the germline.”
 

Step 1: Check Patient Eligibility 

Eligible tumours and the available tests are shown in the National Genomic Test Directory for Cancer (NGTD).

Step 2: Consent the patient

Germline genetic tests have implications for future and family health. Patients should be informed of the implications and be appropriately consented, using a tool such as the Mainstreaming Consent Form to document in the patient record. The below patient information leaflet can be used with or without local trust logo to support patient information giving. 

Please use the generic consent form: 

• Patient Information Leaflet – Patient Information Leaflet – R444.2 NICE approved PARP Inhibitor treatment (Prostate) PIS with SWGLH logo: 

• Patient Information Leaflet – Patient Information Leaflet – R444.2 NICE approved PARP Inhibitor treatment (Prostate) PIS with SWGLH logo:

  Prostate (R444.2) PIS V1.2 TRUST LOGO.pdf285.71 KB

Printing Tips for Patient Information Sheets

• Print in landscape.
• Print on both sides.
• Flip on short edge.

Step 3: Arranging samples and completing the test request form

Blood samples in EDTA tubes (2 x 4ml for adults, 2-5ml for children and 1-2ml for neonates) are required for these tests. Samples should be kept at room temperature or at 4oC and not be frozen before dispatch. 

Please ensure all sample tubes are labelled and accompanied by the test request form

Complete the SWGLH Genomic Test Request form, including:

• The test required.
• Patient diagnosis (confirming eligibility).
• Any relevant family history.
• Who the result should be returned to - a shared results email account for your team is recommended .

Send the completed form with samples:

Step 4: Transportation of samples and request form to the SWGLH

Samples should be transported to the SWGLH through your local pathology systems, unless advised otherwise. These samples should be kept at room temperature or at 4oC and should not be frozen before dispatch. They should ideally arrive within 3 days of sample collection.  

Please refer to the SWGLH Sample Requirements and Transport page for further information. 

Step 5: Results and turnaround times

Results will be returned to the email account or clinician listed on the form

• The national turnaround time for these tests is 42 working days, from sample receipt. Current turnaround times for some tests are considerably shorter than this.
• When special circumstances require a more urgent result, please flag this on the form and contact the Bristol Genetics laboratory to discuss the best approach.
• Once results are received, please see your local mainstreaming guidance for information on management and Clinical Genetics involvement. If you need advice, contact your local Clinical Genetics service: 

rduh.pcgreferrals@nhs.net (or via the Epic system if you are based at the Royal Devon University Healthcare NHS Foundation Trust)

UHBWClinicalGenetics@uhbw.nhs.uk

Step 1: Check Patient Eligibility 

Eligible tumours and the available tests are shown in the National Genomic Test Directory for Cancer (NGTD).

Step 2: Consent the patient

Germline genetic tests have implications for future and family health. Patients should be informed of the implications and be appropriately consented, using a tool such as the Mainstreaming Consent Form to document in the patient record. The below patient information leaflet can be used with or without local trust logo to support patient information giving. 

• Mainstreaming R210 Consent Form: 

• Patient Information Leaflet –  Lynch Syndrome (R210) Patient Information Leaflet with SWGLH logo: 

• Patient Information Leaflet -  Lynch Syndrome (R210) Patient Information Leaflet with space for Trust logo: 

Printing Tips for Patient Information Sheets

• Print in landscape.
• Print on both sides.
• Flip on short edge.

Step 3: Arranging samples and completing the test request form

Blood samples in EDTA tubes (2 x 4ml for adults, 2-5ml for children and 1-2ml for neonates) are required for these tests. Samples should be kept at room temperature or at 4oC and not be frozen before dispatch. 

Please ensure all sample tubes are labelled and accompanied by the test request form

Complete the SWGLH Genomic Test Request form, including:

• The test required.
• Patient diagnosis (confirming eligibility).
• Any relevant family history.
• Who the result should be returned to - a shared results email account for your team is recommended.

Send the completed form with samples:

Step 4: Transportation of samples and request form to the SWGLH

Samples should be transported to the SWGLH through your local pathology systems, unless advised otherwise. These samples should be kept at room temperature or at 4oC and should not be frozen before dispatch. They should ideally arrive within 3 days of sample collection.  

Please refer to the SWGLH Sample Requirements and Transport page for further information. 

Step 5: Results and turnaround times

Results will be returned to the email account or clinician listed on the form

• The national turnaround time for these tests is 42 working days, from sample receipt. Current turnaround times for some tests are considerably shorter than this.
• When special circumstances require a more urgent result, please flag this on the form and contact the Bristol Genetics laboratory to discuss the best approach.
• Once results are received, please see your local mainstreaming guidance for information on management and Clinical Genetics involvement. If you need advice, contact your local Clinical Genetics service: 

rduh.pcgreferrals@nhs.net (or via the Epic system if you are based at the Royal Devon University Healthcare NHS Foundation Trust)

UHBWClinicalGenetics@uhbw.nhs.uk

Educational Resources

Competency frameworks for cancer genomics are also available on the Genomics Education programme website.

The Medical Examiner Service is an independent service that is a legal requirement in England and Wales. It reviews all deaths that are not investigated by a coroner, offering an independent check of the cause of death. 

The Medical Examiner Service aims to: 

• Increase understanding and peace of mind for families.
• Make sure that causes of death are accurate.
• Make sure that appropriate deaths are sent to HM Coroner for investigation.
• Improve learning and patient safety in hospital by providing a review of care. 

Medical Examiners (MEs) are independent senior medical doctors who will not have been involved at all in the care of your loved one.  

They carefully review the clinical notes and meet with the doctor who cared for your loved one. They discuss the person’s care and the cause of death, before the doctor completes the MCCD. 

MEs work with a team of Medical Examiner Officers (MEOs), who are specially trained in the legal and medical elements of death certification. 

A Medical Examiner or Medical Examiner Officer will call you in the next few days. They will explain the wording on the MCCD and answer any questions you have. They will also advise you how to get the death certificate and other forms from the Register Office. 

The Medical Examiner Office can share any feedback to the clinical team or hospital and may ask them to review the care given. This helps identify ways to improve patient care in the future. 

The Medical Examiner Office will do their best to contact the deceased’s next of kin. If you have any questions and have not been able to speak with the team, please contact the Patient Affairs team. 

For more information on the Medical Examiner Service, please visit The Medical Examiner Service - BNSSG Healthier Together

Once completed, the MCCD will be delivered to the Bristol Register Office from the Medical Examiner Office by email (you do not need to collect it in person). 

Sometimes, the hospital doctor must report a death to the coroner before an MCCD is issued. They are a legal expert that must investigate certain types of deaths: 

• Deaths where the cause is unknown.
• Deaths involving violence or trauma.
• Deaths caused by industrial diseases.
• Deaths from acute alcohol poisoning or drug related illnesses.
• Any other deaths thought to be unnatural.

The Coroner’s Office will gather information from the medical staff and the Medical Examiner. Then they will decide if a post-mortem and/or coroner’s inquest is needed.  

In many cases they will give permission to issue the MCCD.  

Coroner’s post-mortem 

A post-mortem (sometimes called an autopsy) is an examination of a body after death. If the death has been referred to the coroner, the MCCD cannot be released or the death registered until this is complete.  

The post-mortem usually takes place within a short time of the death, at the coroner’s mortuary in Flax Bourton. 

The Coroner’s Office will take over from the Patient Affairs Office and Medical Examiner Office. They will  keep you informed of what is happening and guide you in the next steps that you should take. 

The coroner does not require the consent of any other person for this to take place. Funeral directors are familiar with post-mortems and are usually happy to go ahead with funeral arrangements. 

The Coroner’s Office will tell you when they have sent paperwork to the Register Office. You can then make an appointment to register the death. 

The Coroner’s Office can be contacted on 01275 461 920. Opening hours: 07.30 - 15.30, Monday to Friday. 

Coroner’s inquest 

In some circumstances the coroner will proceed to open an inquest. 

The purpose of an inquest is to find out four facts. 

• Who the deceased was.
• When they died.
• Where they died.
• How they died. 

The coroner’s inquest will include: 

• Recording the medical cause of death.
• Completing a post-mortem, in some cases
• Asking you to provide a statement about your loved one, in some cases,
• Asking the team who cared for the deceased to provide statements.  

The coroner will consider this evidence, and there may be a hearing. This is a fact-finding hearing, not to place blame, but to answer the four questions above. You can attend the inquest hearing and ask questions. 

The coroner will then record a conclusion, such as  accident or suicide. The process can take many months to complete, but this does not mean you cannot have a funeral or celebration before it is finished. You will be kept up to date by the Coroner’s Office. 

If your loved one had property or clothing left with the Patient Affairs team, they will contact you to arrange its return or disposal. Jewellery is usually left on the person  and will go to the funeral director, unless the family ask for it to be removed. Please make sure you agree on what should happen with the Patient Affairs Office. Items not collected within 3 months will be disposed of. 

You may wish to come to the hospital’s viewing room to see your loved one. The viewing room is a separate room within the hospital Mortuary. 

To do this, you can make an appointment with the Mortuary Team by phoning 0117 414 0184 between 08:00 - 16:00, Monday to Friday. We do not currently offer viewings on evenings or weekends. 

Alternatively, you may prefer to wait until the deceased is transferred to the care of the chosen funeral director. 

On the rare occasions when the cause of death may be a criminal matter there will be restricted viewing. In these cases, the police will advise you. 

After someone has died it may be possible for their tissues to be donated to help others. Even if they were not a registered donor, the law in England presumes they give consent to donate their tissues. However, family or next of kin will always be consulted before this happens.  

Tissues can only be donated in certain circumstances and time frames: 

• Eyes for corneal transplantation can be donated up to 24 hours after death.
• Heart valves, bone, skin and other tissues can be donated up to 48 hours after death. 

If you choose tissue donation, your loved one will be treated with care and respect, and their appearance will be restored. It won’t delay funeral plans.  

A specialist nurse may contact you to explain the options and answer any questions. Tissue donation is completely voluntary. For more information, call NHS Blood and Transplant on 0800 432 0559 and leave your name and number. A nurse will call you back soon. 

You can register the death if you are: 

• A relative.
• Someone who was there at the death.
• An administrator from the hospital.
• The person making arrangements with the funeral directors.

• The person’s full name at the time of death.
• Any names previously used e.g., maiden name.
• The person’s date and place of birth.
• Their last address.
• Their occupation.
• The full name, date of birth and occupation of a surviving or late spouse or civil partner.
• Whether they were receiving a state pension or any other benefits. 

When you register the death, you will receive the following: 

• A legal death certificate. This is a certified copy in the register of deaths. There is an opportunity to purchase additional death certificates, and you will need to consider how many certificates are needed, as banks, private pension companies and insurance companies require certified copies. Each certificate costs £12.50.
• A Certificate for Burial or Cremation (the ‘green form’), which gives permission for burial or an application for cremation.
• A Certificate for the Department of Work and Pensions Benefit (form BD8) – you may need to fill this out and return it if the person was receiving a state pension of benefits. 

Once you have registered the death you can inform your chosen funeral director that the death is registered so that arrangements can go ahead. 

If the death has been referred to the coroner, you will not be able to register the death until the registrar has received a notification from the Coroner’s Office. 

Local councils 

• Housing Benefit Office
• Council Tax
• Collection of payment for council services
• Libraries
• Electoral Services
• Blue Badges
• Adult Services
• Children’s Services
• Council Housing 

Department for Work and Pensions (DWP) 

• Pension, Disability and Carers’ Service.
• Jobcentre Plus
• Overseas Health Team 

Revenue and Customs 

• Child Benefit
• Child Tax Credit and Working Tax Credit
• Personal Taxation 

Identity and Passport Service 

• Driver and Vehicle Licensing Agency
• Ministry of Defence
• Service Personnel and Veterans Agency
• War Pensions Scheme 

People you might need to inform 

Please ask a member of staff for a printed copy of this patient leaflet if you would like a checklist to complete. 

• Family
• Friends
• Healthcare providers, such as optician, dentist, GP
• Bank or building society, credit card providers
• Premium bonds, long term savings companies (ISAs)
• Anyone holding money for the deceased
• Social Services such as home help or care
• Previous/current place of work (occupational pension), trade unions
• Executor of the estate (will)
• Insurance Companies (car, home, life insurance)
• Residential or nursing home
• Landlord or housing agency
• Mortgage company
• Utility companies (water, electric, gas, phone, internet, TV licence, Internet)
• Hire purchase companies
• Post Office (to redirect mail)
• Cancellation of any upcoming payments
• Transport (to day centres or clubs)
• Deliveries (milk, food boxes, newspapers)
• Return of any borrowed equipment (medical or social)
• Religious organisations (faith leaders)
• Stop any junk mail 

What to do after someone dies - GOV.UK

What to do when someone dies - Age UK

Bristol City Council Bereavement Support 

Get help with funeral costs - GOV.UK

If you need to use a Preventer Inhaler to manage your Asthma, we will soon be able to offer you the opportunity to take part in one of our new research trials.

To learn more, please email: respiratoryresearch@nbt.nhs.uk or call: 0117 4148114

If you get in touch with us, we will ask a few basic questions regarding your asthma history and smoking status.

There is a high prevalence of anxiety, depression and neurocognitive dysfunction which impacts on the wellbeing of patients with severe asthma. These factors may be the result of poorly controlled asthma, the effects of asthma treatments, but also themselves impact on asthma severity. The relationship between these factors is not well understood.

Magnetic resonance imaging (MRI) of the brain demonstrates structural and functional differences between the brains of people with asthma and those without. Though not extensively studied, a small number group of trials have shown a 'normalisation' of brain activity after cognitive behavioural therapy in patients with asthma and depression. The effect of asthma treatments on brain structure and activity requires further investigation.

Mepolizumab is amongst a group of injectable treatments that have revolutionised the treatment of poorly controlled severe eosinophilic asthma. Randomised controlled trial and real-world data shows reduced exacerbations and oral corticosteroid use in patients taking mepolizumab. Trials also show improved asthma-specific quality of life, though there have not been studies that have assessed anxiety, depression, well-being and cognition in detail.

In this observational study we propose to examine the MRI structure and function of the brains of people with severe eosinophilic asthma before and six months after starting mepolizumab as part of routine clinical practice. We will collect detailed health and neurocognitive information to evaluate changes in psychological health and cognition with mepolizumab. We will compare these data, to results in patients with well-controlled asthma. We will assess whether changes seen on MRI brain imaging relate to the direct effect of the mepolizumab on the brain, or of the secondary effects of improved asthma control that is known to be achieved by mepolizumab.

To become participate in this study, find out more information here.

Project Details
Principal Investigator: James Dodd
Planned End Date: TBC
Local Ref: 5409

Many people with chronic obstructive pulmonary disease (COPD) remain very breathless and limited. In some patients, with the appropriate pattern of emphysema, an operation called lung volume reduction surgery is effective at removing the worst affected area of lung. New techniques have been developed where emphysema can be treated using a fibre-optic camera called a bronchoscope. Trials have shown that using a bronchoscope to place endobronchial valves into the airways can be very effective in carefully selected patients and the technique is now being adopted in hospitals across the UK.

This study will collect data from people undergoing these procedures at hospitals across the UK to evaluate how well they work in practice and what factors at baseline influence response. Baseline, three month and 12 month follow up data will be collected. This will include lung function data, measures of exercise capacity, questionnaires about health status and CT scan results. Questions addressed will include:

• What lung function improvement is seen in clinical practice?
• What factors determine who is most likely to respond?
• How safe are the procedures and what is the rate of complications?
• What proportion of people undergoing bronchoscopic procedures require repeat procedures or surgery subsequently?
• Does long term survival differ between people undergoing the different treatments?

The study is supported by The British Lung Foundation and sponsored by Imperial College, London. By building collaboration, the establishment of the network will also produce a structure that will make evaluation of future bronchoscopic techniques easier bringing innovative treatments into play more quickly.

Project Details
Principal Investigator: Dr James Dodd
Planned End Date: 30/06/2026
Local Ref: 4076

When people get chest infections, fluid can sometimes build up around the lung. This is called a parapneumonic pleural effusion. In about 1 in 10 cases, the fluid itself becomes infected, this is called pleural infection. Pleural infection is usually treated by removing the infected fluid and using antibiotics to mop up the left-over infection.

Patients with pleural infection often receive long courses of intravenous antibiotics because doctors are uncertain of how well antibiotics reach the infected pleural fluid and whether bacteria are becoming resistant to them.

The Pleural Antibiotic Concentrations informing Treatment (PACT) study is observational and aims to see how well antibiotics are reaching the infected fluid, and how quickly the bacteria are being killed. To answer this, we will collect samples of pleural fluid from participants who are being treated for pleural infection with pleural drainage. This fluid will be tested to measure how much antibiotic has managed to get into it. We can then tell if the antibiotics are reaching high enough concentrations to kill bacteria. We will also be testing this fluid to see if the bacteria are being killed by the antibiotic or not. In the future, this information may shorten the time patients are treated with intravenous antibiotics and therefore how long they need to stay in hospital.

Project Details
Local Ref: 4581

Background and study aims

Pleural mesothelioma is a cancer that affects the lung lining, caused by asbestos. Despite recent treatment advances, the prognosis is often poor. Prompt diagnosis is vital. A biopsy can diagnose mesothelioma, guide treatment and support compensation claims. However, some people need multiple biopsies, increasing the risk of biopsy-related complications and prolonging the time to diagnosis. Doing additional tests on initial biopsies may increase the chance of diagnosing mesothelioma and avoid repeat biopsies. This would allow anti-cancer treatment to be started sooner and improve survival. The extra tests are not genetic but look for genetic changes in the cancer that allow it to grow and spread. The genetic markers in mesothelioma are called BAP1, p16 and MTAP. If they have disappeared on biopsy mesothelioma is diagnosed. Another study was previously conducted on people with suspected mesothelioma who required further biopsies as their first biopsy did not give a diagnosis  It took place in eight UK centres and recruited 59 patients. This study aims to perform these additional tests on their biopsy samples to see whether this would have made the diagnosis sooner and removed the need for further biopsies. It will investigate how many biopsies could have been avoided, how much time would have been saved, how this may have impacted survival and what cost-savings this would have offered the NHS.

Who can participate?

This study includes the 59 participants in the original TARGET study who were recruited between September 2015 and September 2018. No additional participants will be recruited. Should any participants of the original TARGET trial wish to opt-out, they can contact the main contact below.

What does the study involve?

Biopsy samples taken as part of the participants’ routine clinical care will be tested for the markers of genetic change in mesothelioma (BAP1, MTAP and p16). The ability to make a diagnosis using these tests will be compared with the original diagnostic pathway, which was before the use of these tests.

What are the possible benefits and risks of participating?

The benefits of enrolling are to future patients, whose diagnostic process could be improved, with no additional requirements of TARGET participants. As there are no additional interventions required of participants and this will not impact management, there are no risks identified.

Project Details
Principal Investigator: Prof Nick A Maskell
Duration: October 2022 - July 2025

Funded by the Southmead Hospital Charity

Main contact :  Geraldine.lynch@nbt.nhs.uk

IPF is a progressive scarring lung condition causing coughing and breathlessness. IPF patients often have reflux disease meaning stomach acid may be breathed into the lungs, potentially damaging them. Medicines which stop stomach acid production, proton pump inhibitors (PPIs), can be used to reduce reflux symptoms including heartburn. Some researchers suggest PPIs also reduce IPF progression.

This research aims to see if IPF progresses slower if treated with PPIs. Based on the results, we will be able to recommend whether or not IPF patients should take PPIs.

This trial will involve 298 IPF patients from approximately 37 UK hospitals. At the beginning of the study, we will ask patients to perform breathing tests, and ask those with a cough to use a device to count the number of times they cough in 24hours. We will ask them to answer two questions rating their coughing and breathlessness, and complete questionnaires on their coughing, IPF, sleep habits and general condition. People will be given a PPI, called lansoprazole, or dummy tablets, twice per day for 12 months. They will be given a leaflet telling them what to do about reflux symptoms. At the end of the study, we will repeat these tests and analyse the results. We will record any side effects people may get. If people suffer side effects, they can reduce the dose.

People taking medicines that interact with PPIs or have other serious medical conditions won’t be able to participate. People receiving PPIs will only be able to participate if they can stop taking their medication without their heartburn returning.

The study will be undertaken by doctors and researchers with experience of IPF, reflux disease, PPIs and coughing. We will publicise our results by writing reports for medical publications, media articles and social media.

Project Details
Local Ref: 4672

Interested in taking part? To read the patient Information about FAST MRI Dyamond please go to the FASTMRI Dyamond webpage.

(Diagnostic Yield study for Average MammOgraphic screeNing Density): A multicentre study offering women a FAST MRI scan in addition to their screening mammogram, to see if FAST MRI can find cancers missed by mammography

Aim:

To see if FAST MRI, a new imaging test, can detect cancers that have been missed by mammograms for women with average breast density at their first screening mammogram (age 50-52).

Background:

Finding breast cancers early saves lives. The NHS breast screening programme uses mammograms tofind breast cancers early but sometimes a mammogram misses a cancer which keeps growing until the woman finds it herself. MRI (Magnetic Resonance Imaging) detects aggressive cancers better than mammograms but is expensive and the NHS uses it to screen only women at very high risk. FAST MRI is a shorter MRI test which might benefit more women by finding more breast cancers earlier and saving more lives.

Every woman’s breasts are different. Breast composition affects how they look on mammograms. Women with denser breasts are more likely to have their cancers missed on mammograms because dense breast tissue can hide a cancer. Of four density categories (A,B,C and D), A is the least dense and D is the densest. At age 50-52, about 8 of 10 women will be in one of the middle categories, B or C, about half in each. We already know from previous research that FAST MRI can find cancers missed by mammograms in women with denser breasts (C and D). But women with average breast density (B) also have cancers missed, because mammograms are better at finding some types of cancer than others. We want to find out if FAST MRI can detect additional cancers for this group of women (category B). Women in category A are least likely to benefit as their mammograms show any cancers present more clearly and easily.

Design and methods used:

We will invite women aged 50-52, the age when women at average risk of breast cancer are first invited for an NHS screening mammogram. We will use computer software to measure women’s breast density from their mammogram and invite women with breast density in category B and a normal mammogram result to have a FAST MRI scan. 1,000 women will be scanned at 4 NHS sites, chosen for the ethnic diversity of the screened population and the experience the site has in working with FAST MRI. This choice of NHS sites will ensure our sample is representative of the UK. NHS professionals who have completed FAST MRI reader training will interpret the FAST MRI scans. We will count the total number of cancers detected by FAST MRI and record the types, aggressiveness and size of cancer found. We will count how many women need further tests but turn out not have cancer. We will ask women to share with us their experience of having a FAST MRI. The results will help us decide which women should be included in a future FAST MRI trial to measure if FAST MRI is clinically and cost effective for the NHS by finding breast cancers earlier and saving lives.

Patient and public involvement (PPI):

Patients and the public are integral in our work and we have ongoing support from:

1. Breast Cancer Unit Support Trust (BUST)
2. National Cancer Research Institute (NCRI) Breast Group
3. Independent Cancer Patients’ Voice (ICPV)

Our two lay research team members with personal experience of breast cancer and of breast screening will work with the wider PPI group to write public-facing documents so that participants and the public understand the research. They will also work to increase diversity, equality and inclusion in the PPI group.

Dissemination:

We will publish the results in academic journals and present at international meetings. Our PPI network will help us to share the results with charities and support groups locally and nationally.

Funded by the NIHR and MRC via the EME funding stream (NIHR 150502).

Project Details

Chief Investigator: Dr Lyn Jones

Co-Lead: Dr Rebecca Geach

Planned End Date: 01/11/2026

Local Ref: 5273

(OPtimisation of the FAST MRI protocol: an Evaluation of what makes a good breast MRI through detailed Analysis of scans from multiple NHS sites)

Background:

Finding breast cancer early saves lives. The NHS Breast Screening Programme (NHSBSP) uses mammograms to detect early breast cancers. However, not all cancers show on a mammogram so a cancer can be missed and continue to grow until the woman finds it herself. Magnetic Resonance Imaging (MRI) scans are better at detecting cancers than mammograms. However, MRI is expensive, and the NHS only uses it to screen women classed as high risk of developing breast cancer.

Recent studies have shown that using only part of the full breast MRI scan detects cancer equally well as the full scan, but is a much quicker scan with lower costs. This technique is called FAST MRI and has the potential to save more women’s lives by finding breast cancers earlier than a mammogram and providing value for money for the NHS. A group of research studies led by North Bristol NHS Trust aim to develop a better breast screening programme using FAST MRI for women who currently have mammograms, to screen for breast cancer.

How easy it is to see a breast cancer on an MRI scan depends on the scan quality and the technical details of the scan, known as the protocol. Quality control is therefore crucial for breast screening to optimise the detection of cancers.

This pilot study will develop a standardised and optimised protocol to be used in a separate multicentre trial of FAST MRI for women having their first screening mammogram (DYAMOND).

Aims:

1. Define the parameters that make a good quality FAST MRI scan.
2. Standardise the scan protocol across NHS sites to enable quality control during FAST MRI research trials and future clinical practice.

Design and Methods:

Our study will analyse breast MRI scans from different scanners across NHS sites within the FAST MRI Research Programme. Anonymised scans will be sent electronically to a panel of Breast Radiologists who will each score the scans for multiple aspects of scan quality. A team of Medical Physicists will also extract the numerically measurable aspects within each of the sites’ scan protocol and images. These two information sets, radiologists’ visual assessments and objectively measured values, will then be analysed to discover which settings make the optimal FAST MRI scan for each type of MRI scanner used. Site specific recommendations will be made to improve scan quality.

Results:

Study in progress.

Funded by Southmead Hospital Charity Research Fund.

Project Details

Principal Investigator: Dr Katherine Klimczak

Planned End Date: 31/12/2024

Local Ref: 5268

(EvaluatioN of an Artificial Intelligence (AI) Tool developed within and owned by the NHS to accurately measure mammographic breast Density): Selection for personalised screening with FAST MRI.

Background:

Finding breast cancer early saves lives. The NHS uses mammograms to try and detect early breast cancers. However, as mammograms do not show some cancers very well, a cancer can be missed and continue to grow until the woman finds it for herself. MRI (Magnetic Resonance Imaging) is a test that can find cancers better than mammograms, but it is expensive and so the NHS only uses it to screen women at very high risk of breast cancer. A quicker, shorter MRI test is now available called FAST MRI. Not only might this test benefit more women, it may also provide better value for money for the NHS to find breast cancers early and save lives. 

Every woman’s breasts are different. One way they differ is in a characteristic known as mammographic or breast density, which affects how they look on mammograms. Women with denser breasts can have their cancers missed on mammograms, as the dense normal tissue can hide the cancer. FAST MRI is better at finding these cancers.

To find out which women have dense breasts and could benefit from a FAST MRI, the mammograms need to be studied and measured. Currently, breast density is looked at and estimated by the radiologist but as each radiologist might view images slightly differently, results for breast density might not always be correct. There are now better systems to do this using (expensive) technology.

Aims:

To evaluate the accuracy and reliability of a breast density measurement tool. This will provide the National Breast Screening Programme (NHSBSP) with the ability to describe a woman’s breast density. If this tool is successful, it will further enable the North Bristol NHS Trust led FAST MRI research programme to develop a better breast screening programme.

Methods:

Our study uses an NHS developed and owned artificial intelligence (AI) software tool to automatically categorise the breast density. The cost to other NHS organisations will therefore be much lower when compared to commercial software. In this study we have tested our tool on anonymised mammograms, held in a research database called OPTIMAM, and compared the results to measurements made by commercial technology.

Our study looked at women aged 50-55, the age when women at average risk of breast cancer in the population are first invited to attend for an NHS screening mammogram.

Results:

The results of this study will be presented at the Symposium Mammographicum Conference, June 2023

Funded by Southmead Hospital Charity Research Fund.

Project Details
Principal Investigator: Dr Katherine Klimczak
Planned End Date: 01/04/2023
Local Ref: 5086

A study to improve FAST MRI interpretation training and to enhance Breast Clinician and Advanced Practitioner Radiographer understanding of breast MRI at multidisciplinary team (MDT) discussions.

Background:

FAST MRI (a shortened form of breast MRI) has been developed to address limitations of full protocol breast MRI (fpMRI), by shortening the time needed to acquire and to report the scan. FAST MRI diagnostic accuracy is similar to fpMRI and therefore has potential for wider use in screening but to roll it out on a larger scale more readers skilled at interpreting FAST MRI would be needed. Initial evaluation showed NHSBSP mammogram readers could be trained to interpret FAST MRI with a single day of structured training, but novice MRI readers were still learning at the end of the final assessment task and therefore it is likely that further training could further improve their performance. The current study aims to see if further training can enable novice MRI readers to match the performance of experienced breast MRI readers at FAST MRI interpretation. The improvement in novice reader performance during the training will be monitored to enable evaluation of their "learning curve” so that we can find out how much training mammogram readers need to enable them to interpret FAST MRI scans in clinical practice.

Methods:

Mammogram readers from seven NHS sites in England will undertake the developed North Bristol FAST MRI interpretation training programme. The final assessment task of the training programme has been updated for this study (since its use in the previous Multi Centre Reader Training Study) so that feedback (the true results of each FAST MRI scan) is given to the readers immediately after they have recorded their opinion about the scan. This modification to the assessment task is known as "formative assessment” in educational theory and has been shown in education research to be an effective teaching tool. Because the FAST MRI scans of the final assessment task are presented to each reader in a different random order, we will be able to map the learning curve of each reader as they complete the final (formative) assessment task. 

Results:

The results of this study will be presented at the Symposium Mammographicum Conference, June 2023

Funded through the National Breast Imaging Academy by Health Education England.

Project Details
Principal Investigator: Dr Liz O’Flynn
Planned End Date: 30/12/2022
Local Ref: 5041

Background:

To be able to get high quality FAST MRI images it is important that the correct protocol (information/sequences programmed into the scanner) is optimised. To do this test (phantom) breast need to be developed to trial the protocols to put into the MRI machine.  

Aims:

To develop breast test objects to ensure an optimum FAST MRI protocol (the information put into the MRI scanner to run the scan) and develop a quality assurance (QA) programme that can be used across different sites and MR scanner vendors.

Methods:

This phantom development work includes the design and construction of 2 magnetic resonance imaging (MRI) test objects that will be used for quality assurance (QA) tests of MR scanners at centres participating in the FAST MRI project.

One of these test objects will be used to assess the dynamic range of the dynamic contrast enhanced (DCE) sequence and the other the resolution in 3 dimensions. The MRI test objects will be trialled at NBT initially in order to finalise the design. 

Results:

The results of this study will be presented at the Symposium Mammographicum Conference, June 2023

Funded by the National Institute of Health Research (NIHR) Research for Patient Benefit funding stream.

Project Details
Principal Investigator: Dr Lyn Jones
Planned End Date: 30/10/2022
Local Ref: 4543

Background:

After the promising results of the single centre study, the FAST MRI training programme was awarded an NIHR grant to expand and develop the FAST MRI training further.

Aims:

The aim of this study was to refine and pilot a training programme for FAST MRI interpretation within the NHS Breast Screening Programme (NHSBSP) workforce, to support the delivery of a future multicentre study of FAST MRI versus mammogram for breast cancer screening.

• Produce an electronic version of a standard teaching tool and data collection tool working in close partnership with NHS based SciCom team (Workstream 1).
• Pilot the standard teaching tool across six NHS sites within the South West region, UK and collect data on the accuracy and speed of FAST MRI interpretation following training (Workstream 2).

Methods:

The aim was achieved in two work streams:

• Workstream 1: Production of electronic versions of a standard teaching tool and of a data collection tool.
• Workstream 2: Pilot the standard teaching tool across six NHS sites (NHSBSP screening units) within the South West region of England (Truro, Plymouth, Taunton, Avon, Cheltenham and Swindon) and collect data on the accuracy and speed of FAST MRI interpretation following training. In addition, a Budget Impact Analysis to assess potential cost savings and affordability to the NHS to be assessed by the research team’s Health Economist as part of this workstream.
• Training: The teaching tool was used to train at least 12 readers from six centres to read FAST MRI. One day group training replaced the one-to-one training (used in the previous single centre study). This was made possible by the electronic teaching device.
• Follow-up interview: Study participants who gave consent to be contacted for future studies were invited to take part in a follow up interview to find out more information about how the readers felt about the study.

Results:

Jones LI, et al., Evaluating the effectiveness of abbreviated breast MRI (abMRI) interpretation training for mammogram readers: a multi-centre study assessing diagnostic performance, using an enriched dataset. Breast Cancer Research. 2022 Jul; 24(1):55.

Conclusions:

• NHSBSP mammogram readers who completed the FAST MRI training programme achieved diagnostic performance at FAST MRI interpretation (in the final assessment task of the training programme) within international benchmarks (standards) published for full protocol breast MRI.
• The single day of training was not enough to enable mammogram readers who were new to breast MRI to interpret FAST MRI quite as well as mammogram readers who were experienced in full protocol breast MRI interpretation.
• Mammogram readers who were new to breast MRI interpretation continued to improve at how well they could detect breast cancers from FAST MRI scans during the final assessment task of the training programme. This showed that they were still learning during the final task and means that their diagnostic performance might improve further if given further training.

Funded by the National Institute of Health Research (NIHR) Research for Patient Benefit funding stream.

Project Details
Principal Investigator: Dr Lyn Jones
Study Completion: 07/09/2020
Local Ref: 4543

Background:

Mammographic screening programmes result in both over diagnosis and under diagnosis of breast cancer. Under diagnosis leads to cancers presenting symptomatically between screening visits (interval cancers), and to cancers being detected by screening only once they have already reached more complex and life-threatening stages.Although MRI is the most sensitive method to detect breast cancer, currently only women classified as high risk (>30% lifetime risk) are offered screening MRI in the UK. However, in the future, personalised screening could enable larger numbers of women to be offered different screening regimes, each incorporating different imaging modalities, according to their level of risk.

Finding breast cancer early saves lives, and there is therefore a need to develop cost-effective imaging tests that will benefit women at risk of breast cancer by finding significant disease early. First post-contrast Acquisition SubtracTed (FAST) MRI is a type of abbreviated (shortened) breast MRI. FAST MRI is essentially as accurate at breast cancer detection as full protocol breast MRI, but is much faster to acquire and report. This technique might benefit more women than are currently offered screening with full protocol breast MRI. FAST MRI may be especially useful for women with dense breasts, since cancers obscured by dense tissue on mammograms are often visible on MRI

Aims:

The aim of this study was to explore whether NHS breast screening programme (NHSBSP) mammogram readers can learn to effectively interpret FAST MRI with less than one day’s additional training and to match the capabilities of expert breast MRI readers at this task in terms of accuracy and speed of interpretation.

Methods:

FAST MRI images were created by using previously acquired full protocol breast MRI scans. The anonymised images were reformatted and simplified into a form equivalent in its display to a FAST MRI. Using these FAST MRI images, training was offered to colleagues at Bristol Breast Care Centre.

Four consultant radiologists who were qualified to report full protocol breast MRI and four screening mammogram film readers who had not previously been trained to report MRI were trained to read FAST MRI. They were shown a set of training images with answers in a one to one session with the Chief Investigator, and the length of time taken to train each person was recorded.

Results:

The findings showed that the brief structured training carried out in the study enabled multi-professional mammogram readers to achieve similar accuracy at FAST MRI interpretation to that of the consultant radiologists experienced at breast MRI interpretation.

For more information about this study, published results can be found on the British Institute of Radiology website (main results), European Journal of Radiology website (training methodology) and the Pub Med website (review of published literature).

Funded by North Bristol NHS Trusts’ Research Capability Fund.

Project Details
Principal Investigator: Dr Lyn Jones
Study Completion: 26/02/2019
Local Ref: 4002

Consultant Radiologist - FAST MRI Programme Lead

Dr Lyn Jones is a Consultant Radiologist specialising in Breast Care. Lyn was struck by the potential for FAST MRI to pick up aggressive breast cancers earlier for women, regardless of their mammographic density, and so she set up the FAST MRI Programme of Research at North Bristol NHS Trust. She became Chief Investigator for local and National Institute for Health and Care Research (NIHR), Research for Patient Benefit (RfPB) grants, designing and testing a training programme for NHS Breast Screening Programme (NHSBSP) mammogram readers to learn to interpret FAST MRI.

Lyn leads the FAST MRI Programme of Research and is currently Chief Investigator for the FAST MRI DYAMOND Study, funded jointly by the Medical Research Council (MRC) and the NIHR, through a grant from their Efficacy and Mechanism Evaluation (EME) funding stream. The study will be the first in the UK to offer a FAST MRI to women who have average mammographic density and are having their first NHS screening mammogram.

Lyn lectures nationally and internationally on breast MRI and has written sessions on breast MRI for the National Breast Imaging Academy.

Consultant Radiologist

Dr Geach is a Consultant Radiologist and the Radiology Research Lead at North Bristol NHS Trust. Becky has been part of the FAST MRI Programme for nearly five years previously co-leading on the FAST MRI reader training. She is now a co-lead for the EME NIHR funded grant FAST MRI DYAMOND study which started in May 2023.

Becky has also presented at a number of national conferences including a poster on “Abbreviated Breast MRI – A systematic review” which was awarded third prize in the scientific poster category at the British Society of Breast Radiology Annual Meeting. She is the lead author of the FAST MRI Team’s systematic review and meta-analysis of abbreviated breast MRI, published in Clinical Radiology in 2021.

Consultant Radiologist

Katherine graduated from the University of Wales in 2008 and worked in Swansea before crossing the border to undertake Radiology training in the Severn Deanery.  She has been a Consultant Breast Radiologist at North Bristol NHS Trust since 2018 and has been a contributing member of the FAST MRI Research Programme since 2020.  Katherine is currently the Chief Investigator for the FAST MRI ENAID project and FAST MRI OPERA study.

FAST MRI Programme Manager

Sadie is the FAST MRI Programme Manager. Sadie co-ordinates the grants, approvals, contracts and site set up for new studies and general management of the studies in progress to maintain oversight of the study, ensuring they run to time, target and protocol.

Senior Research Fellow

Dr Sam Harding is a Senior Research Fellow at North Bristol NHS Trust. She is a Health Psychologist and PhD. Sam is a mixed methodologist researcher with additional expertise in scoping and systematic reviews.  Her research portfolio covers a diverse set of medical fields from Hyperbaric Medicine, Speech and Language Therapy and Head and Neck cancer, to working with the FAST MRI team. Sam’s interests lay in quality of life and the impact of medical interventions on chronic conditions. She also investigates lived experiences in relation to treatments, interventions and education. Sam has worked on a number of FAST MRI projects including qualitative research, supporting Public & Patient Involvement.

Cancer Trials Lead, Warwick Clinical Trials Unit

Professor Janet Dunn is the Deputy Director of Warwick Clinical Trials Unit (CTU) at Warwick Medical School, University of Warwick. She has over 25 years clinical trials experience. Janet has been instrumental in supporting the set up of the FAST MRI programme and the running of the studies with wide knowledge.

Associate Professor, Warwick Clinical Trials Unit

Dr Andrea Marshall is an Associate Professor at Warwick Clinical Trials Unit (CTU) at Warwick Medical School, University of Warwick. Specialising in statistical design and analysis of randomised clinical trials Andrea has led all the quantitative analysis for the FAST MRI studies.

Professor of Screening & Test Evaluation

Professor Sian Taylor-Phillips leads Warwick Screening at Warwick Medical School, University of Warwick. Sian has brought a wealth of screening experience to the FAST MRI programme, her research focuses on synthesising evidence for national policy advisers such as the UK National Screening Committee and NICE.

Consultant Radiologist

Dr Sarah Vinnicombe is currently Lead Breast Radiologist, Deputy Director of Screening and Consultant Radiologist at the Thirlestaine Breast Centre, Cheltenham. Until 2011, she was lead Breast Radiologist and Director of Breast Screening at Barts Health, when she moved to the University of Dundee to take up a Senior Lectureship in Cancer Imaging, a post she held till 2018.

In Cheltenham, she leads on breast imaging research and is PI and co-investigator on a number of national and local studies. Her main research interests are in breast density, risk adapted screening, imaging of response to neoadjuvant therapy and novel breast imaging techniques. She sits on the NHS BSP Research Advisory Committee and is a member of the NHS BSP Clinical Professional Group, advising on all radiological aspects of the Breast Screening Programme.

She is a Trustee of Symposium Mammographicum and Vice Chair of the Organising Committee and has been President of the British Society of Breast Radiology since November 2019.

Statistician & Methodologist, Research Design Service

Chris is a statistician and methodologist for the Research Design Service of the NIHR. Chris has worked with Lyn from the start, from when it was all just an idea. With Chris’s expertise in statistics, clinical trials, research ethics and health economics he has supported Lyn to set up the FAST MRI programme and continues to be a valued advisor.

Professor of Health Economics

Professor Claire Hulme is a Professor of Health Economics, Director of the Institute of Health Research at the University of Exeter. Claire has been invaluable, supporting the FAST MRI Programme with reviews of the cost and cost effectiveness of imaging and Budget Impact Analysis. Claire was also invited to present her abstract “Estimating the cost impact of including Magnetic Resonance Imaging (MRI) in the National Health Service Breast Screening Programme (NHSBSP) for population-risk women in England” at the Symposium Mammographicum in February 2021.

Head of Scientific Computing

Professor Mark Halling Brown is the Head of Scientific Computing at Royal Surrey County Hospital. He leads a team in the development of Clinical Systems and databases, services and techniques for visualization, analysis and investigation of medical imagery, improvement of QA services, clinical applications and AI/Machine learning on medical images.

His team has developed the OPTIMAM project has led to the creation of one of the world’s largest mammography image databases (OMI-DB). Our recent focus involves the development and validation of AI tools for use in healthcare.

Consultant Breast Radiologist

Dr Elizabeth O’Flynn is a Consultant Breast Radiologist at St George’s Hospital in London. Dr O’Flynn completed an MD thesis in breast imaging while at the Institute of Cancer Research and Royal Marsden Hospital. She has published on breast related topics, has a book chapter on functional breast imaging techniques and lectures nationally and internationally on all aspects of breast imaging.

NIHR Clinician Scientist

Miss Shelley Potter is an NIHR Clinician Scientist, Associate Professor of Oncoplastic Breast Surgery and Consultant Oncoplastic Breast Surgeon, dividing her time between the University and the Bristol Breast Care Centre at North Bristol NHS Trust.

Shelley’s research interest include using pilot and feasibility work to inform the design and conduct of large-scale RCTs in breast surgery. She co-led the NIHR funded iBRA (Implant Breast Reconstruction evAluation) study which aimed to inform the feasibility, design and conduct of an RCT in implant-based breast reconstruction and is now leading Best-BRA, an implant reconstruction RCT. 

Shelley will be supporting the FAST MRI study with her expertise on cancer treatments and outcomes.

The BIRCH team provides scientific and technical support to a wide range of services within UHBW, external NHS Trusts, NHS screening programmes and other institutions in the region. We have expertise in Magnetic Resonance Imaging (MRI), ultrasound (US) and scientific computing (image processing). Our key services in MRI cover procurement, acceptance and quality assurance (QA) testing, MR safety expert advice, image optimisation and adoption of new techniques. We have also developed in-house phantoms and software for semi-automated MRI QA image analysis.

Personnel involved:

• Dr Sian Curtis (PhD) is a registered Principal Clinical Scientist specialising in MRI and ultrasound and has worked at UHBW for over 20 years. She is a corresponding member (and previous Chair) of the Institute of Physics and Engineering in Medicine’s Magnetic Resonance Special Interest Group (IPEM MR SIG), a British Medical Ultrasound Society (BMUS) council member and the BMUS representative on the IPEM Ultrasound and Non-Ionising Radiation SIG (IPEM UNIR SIG).
• Mr Ron Hartley-Davies is a registered Principal Clinical Scientist specialising in MRI and scientific computing and has worked at UHBW for over 20 years. He is the designated MR Safety Expert (MRSE) for UHBW.
• Mr Jonathon Delve is a registered Clinical Scientist specialising in MRI and scientific computing.
• Dr Holly Elbert (PhD) is a registered Clinical Scientist specialising in MRI, ultrasound and scientific computing. She did a DPhil in Astrophysics before training in Medical Physics at UHBW from 2016-2019. During her training she did projects in phantom construction and functional MRI analysis, and a placement at the Cardiff University Brain Research Imaging Centre on diffusion MRI analysis.

The FAST MRI programme includes several Public and Patient Involvement representatives. They sit on the Trial Steering Committee giving input into the conduct of the study progress of the trial/project, adherence to the protocol, and the consideration of new information of relevance to the research question. They comment on the rights, safety and well-being of participants and proposals for substantial protocol amendments and provide advice to the sponsor and funder regarding approvals of such amendments.

Their membership is invaluable as they are able to ensure that patients are at the centre of the research conducted as part of the FAST MRI programme; reviewing documentation to make sure that it is written in lay language and that results from the studies are disseminated to the general public.

Public Representatives:

• Jenny Wookey is the Chair of BUST (North Bristol Trust’s Breast Cancer Unit Support Trust).
• Jan Rose is a member of the ICPV (Independent Cancer Patient’s Voice) and National Cancer Research Institute Breast Group.
• Helen Matthews works for the civil service in educational policy. She was diagnosed with high grade ductal carcinoma in situ (DCIS) in November 2021 following a routine screening mammogram, underwent treatment and is now continuing to lead a healthy and active life. She has joined the team to encourage the expansion and effectiveness of routine testing, knowing that it has saved her life.